169 related articles for article (PubMed ID: 30587451)
1. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
[TBL] [Abstract][Full Text] [Related]
2. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
[TBL] [Abstract][Full Text] [Related]
3. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
4. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
5. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
6. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD).
Dong J; Wang TL; Lu J; Ding CZ; Hu L; Hu G; He H; Zeng X; Li X; Sun D; Zhu Y; Shen L; Gu Q; Chan CC; Xia Y; Li J; Chen S
Bioorg Med Chem Lett; 2020 Nov; 30(22):127601. PubMed ID: 33035677
[TBL] [Abstract][Full Text] [Related]
7. An expeditious synthesis of tamoxifen, a representative SERM (selective estrogen receptor modulator), via the three-component coupling reaction among aromatic aldehyde, cinnamyltrimethylsilane, and beta-chlorophenetole.
Shiina I; Sano Y; Nakata K; Suzuki M; Yokoyama T; Sasaki A; Orikasa T; Miyamoto T; Ikekita M; Nagahara Y; Hasome Y
Bioorg Med Chem; 2007 Dec; 15(24):7599-617. PubMed ID: 17904372
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
[TBL] [Abstract][Full Text] [Related]
11. An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells.
Zhao X; Li M; Sun W; Fan J; Du J; Peng X
Chem Commun (Camb); 2018 Jun; 54(51):7038-7041. PubMed ID: 29873358
[TBL] [Abstract][Full Text] [Related]
12. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
14. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
[TBL] [Abstract][Full Text] [Related]
15. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
16. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
Lv W; Liu J; Skaar TC; Flockhart DA; Cushman M
J Med Chem; 2015 Mar; 58(6):2623-48. PubMed ID: 25751283
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
Liu J; Zheng S; Akerstrom VL; Yuan C; Ma Y; Zhong Q; Zhang C; Zhang Q; Guo S; Ma P; Skripnikova EV; Bratton MR; Pannuti A; Miele L; Wiese TE; Wang G
J Med Chem; 2016 Sep; 59(17):8134-40. PubMed ID: 27529700
[TBL] [Abstract][Full Text] [Related]
19. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
